Is HEB a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,104 people get HEB articles and Market Currents by email alert.

Get email alerts on HEB »

HEADLINES:

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2013

GlobeNewswire (May 8, 2013)
Biotechs Ramping Up On China's Avian Flu Outbreak
David Zanoni • Mon, Apr 8 • 12 Comments
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2012

GlobeNewswire (Mar 18, 2013)
Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection(R) in Argentina

GlobeNewswire (Mar 4, 2013)
Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome

GlobeNewswire (Feb 4, 2013)
FDA Advisory Committee Makes Recommendations on Ampligen (R) for Chronic Fatigue Syndrome

GlobeNewswire (Dec 21, 2012)
2 Biotech Stocks That Could Be Prime Candidates For The Short Seller
Matt Schilling • Fri, Dec 21, 2012 • 6 Comments
Stock Watch Wednesday, 19 December
VFC's Stock House • Wed, Dec 19, 2012 • 3 Comments
Hemispherx Faces FDA Day
EnhydrisPECorp • Wed, Dec 19, 2012 • 28 Comments
Strong Small Cap Biopharma Catalyst Trades And Investments For Consideration
Scott Matusow • Tue, Dec 18, 2012 • 29 Comments
Hemispherx's Ampligen Is Unlikely To Receive FDA Approval
Beacon VP Investments • Tue, Dec 18, 2012 • 27 Comments
Ampligen: The Political Calculus Has Changed
EnhydrisPECorp • Wed, Dec 12, 2012 • 25 Comments
Tuesday's Small-Cap Biopharma Catalyst Trade List
Scott Matusow • Tue, Dec 11, 2012 • 19 Comments
Hemispherx's Ampligen For The Treatment Of Chronic Fatigue Syndrome: A Regulatory Conundrum
Richard Daifuku • Sun, Dec 9, 2012 • 12 Comments
Hemispherx Biopharma: A Voice Of Reason Amid The Din
EnhydrisPECorp • Tue, Dec 4, 2012 • 17 Comments
3 Stocks With High Alphas: Acadia, Hemispherx, And Vringo
EnhydrisPECorp • Thu, Nov 8, 2012 • 6 Comments
Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2012

GlobeNewswire (Nov 2, 2012)
Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012

GlobeNewswire (Oct 22, 2012)
Savient Pharmaceuticals May Continue To Run Higher
Scott Matusow • Tue, Oct 9, 2012 • 7 Comments
3 Best Biotech Stocks For This Week (Part IV)
Jorge Aura • Wed, Oct 3, 2012 • 4 Comments

Hemispherx Biopharma: A Voice Of Reason Amid The Din
EnhydrisPECorp • Tue, Dec 4, 2012 • 17 Comments

Hemispherx Faces FDA Day
EnhydrisPECorp • Wed, Dec 19, 2012 • 28 Comments
Hemispherx's Ampligen Is Unlikely To Receive FDA Approval
Beacon VP Investments • Tue, Dec 18, 2012 • 27 Comments
Ampligen: The Political Calculus Has Changed
EnhydrisPECorp • Wed, Dec 12, 2012 • 25 Comments
Hemispherx's Ampligen For The Treatment Of Chronic Fatigue Syndrome: A Regulatory Conundrum
Richard Daifuku • Sun, Dec 9, 2012 • 12 Comments
Hemispherx Biopharma: A Voice Of Reason Amid The Din
EnhydrisPECorp • Tue, Dec 4, 2012 • 17 Comments
Can Hemispherx Find Success In The Chronic Fatigue Market?
Lewis Adams • Mon, Oct 1, 2012 • 18 Comments
Law Firms Going After Hemispherx
M. E. Garza • Fri, Nov 13, 2009 • 6 Comments
Hemispherx Biopharma: Investors Growing Tired of CFS Drug Delays
EP Vantage • Mon, Nov 9, 2009 • 4 Comments
Hemispherx Biopharma Could Become a Nice Rebound Story
VFC's Stock House • Thu, Nov 5, 2009 • 12 Comments
HEB: Pressure Mounting on FDA to Approve Ampligen for Chronic Fatigue
David White • Tue, Jul 14, 2009 • 32 Comments
Buy Hemispherix Before Ampligen's FDA Approval
David White • Wed, Jun 24, 2009 • 33 Comments
Hemispherx's Ampligen: Fact vs. Fiction
Michael Catalin Vlaicu • Tue, Jun 9, 2009 • 13 Comments
Hemispherx's Ampligen Also Combats Avian Flu
Michael Catalin Vlaicu • Thu, Jun 4, 2009 • 6 Comments
Hemispherx Biopharma: Hot and Likely to Get Hotter
David White • Wed, Jun 3, 2009 • 49 Comments
Hemispherx Biopharma: Does Patience Pay Off in Pharmaceuticals?
Hilary Kramer • Mon, Apr 16, 2007 • 1 Comment
Is Hemispherx BioPharma Undervalued?
Geert Vandeplassche • Thu, Feb 8, 2007 • 6 Comments
Hemispherx Biopharma Is Worth The Risk
Hilary Kramer • Wed, Dec 20, 2006 • 3 Comments

Biotechs Ramping Up On China's Avian Flu Outbreak
David Zanoni • Mon, Apr 8 • 12 Comments
2 Biotech Stocks That Could Be Prime Candidates For The Short Seller
Matt Schilling • Fri, Dec 21, 2012 • 6 Comments
Stock Watch Wednesday, 19 December
VFC's Stock House • Wed, Dec 19, 2012 • 3 Comments
Strong Small Cap Biopharma Catalyst Trades And Investments For Consideration
Scott Matusow • Tue, Dec 18, 2012 • 29 Comments
Tuesday's Small-Cap Biopharma Catalyst Trade List
Scott Matusow • Tue, Dec 11, 2012 • 19 Comments
3 Stocks With High Alphas: Acadia, Hemispherx, And Vringo
EnhydrisPECorp • Thu, Nov 8, 2012 • 6 Comments
Savient Pharmaceuticals May Continue To Run Higher
Scott Matusow • Tue, Oct 9, 2012 • 7 Comments
3 Best Biotech Stocks For This Week (Part IV)
Jorge Aura • Wed, Oct 3, 2012 • 4 Comments
Interferon's Role In Flu Control Shouldn't Be Underestimated
Jessica King Holden • Wed, Jan 11, 2012 • 4 Comments
Euphoria From Inhibitex Acquisition Spreads To Other Firms
M. E. Garza • Wed, Jan 11, 2012 • 4 Comments
Vical: A Review Of, And Update On, Allovectin
Theodore Cohen • Mon, Jan 9, 2012 • 17 Comments
Equities Update: Flat Finish as Energies Weigh
Midnight Trader • Wed, Dec 2, 2009 • 4 Comments
BioMed Momentum Index: A Pause that Refreshes or More Pain to Come?
Mike Havrilla • Thu, Oct 29, 2009 • 1 Comment
FDA Calendar Extreme Trades: 85 Single Digit Stocks
Mike Havrilla • Wed, Oct 14, 2009 • 4 Comments
Extreme FDA Trades: 30 Stocks Under 5 Bucks
Mike Havrilla • Sun, Aug 2, 2009 • 23 Comments
FDA Calendar: 2H09 Binary Event Trades
Mike Havrilla • Mon, Jul 27, 2009 • 4 Comments
Small Biopharma Ponderings
VFC's Stock House • Mon, Jul 27, 2009
FDA Calendar Updates: Schering-Plough, Hemispherx, Bovie Medical
Mike Havrilla • Thu, Jul 23, 2009
Key Developments for Spectrum Pharma, Human Genome Sciences and Hemispherx Biopharma
M. E. Garza • Tue, Jul 21, 2009 • 5 Comments
Extreme FDA Trades: 20 Stocks Under 5 Bucks
Mike Havrilla • Tue, Jul 21, 2009 • 3 Comments

There are no Transcripts on HEB.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2013

GlobeNewswire (May 8, 2013)
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2012

GlobeNewswire (Mar 18, 2013)
Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection(R) in Argentina

GlobeNewswire (Mar 4, 2013)
Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome

GlobeNewswire (Feb 4, 2013)
FDA Advisory Committee Makes Recommendations on Ampligen (R) for Chronic Fatigue Syndrome

GlobeNewswire (Dec 21, 2012)
Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2012

GlobeNewswire (Nov 2, 2012)
Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012

GlobeNewswire (Oct 22, 2012)
Hemispherx Biopharma Files for Treatment Expansion in Argentina for Alferon N Injection(R) for Hepatitis C

GlobeNewswire (Oct 1, 2012)
Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen(R) for Chronic Fatigue Syndrome

GlobeNewswire (Sep 24, 2012)
Hemispherx Biopharma Reports on Annual Stockholder Meeting

GlobeNewswire (Sep 19, 2012)
Hemispherx Biopharma to Present at the Rodman and Renshaw 14th Annual Healthcare Conference

GlobeNewswire (Sep 6, 2012)
Cirrus Logic, Synopsys Among Stocks Setting 52-Week Highs Thursday

at Fox Business (Aug 23, 2012)
Cirrus Logic, Synopsys Among Stocks Setting 52-Week Highs Thursday

at Fox Business (Aug 23, 2012)
Cirrus Logic, Synopsys Among Stocks Setting 52-Week Highs Thursday

at Fox Business (Aug 23, 2012)
Cirrus Logic, Synopsys Among Stocks Setting 52-Week Highs Thursday

at Fox Business (Aug 23, 2012)
FDA Accepts Complete Response Submission Regarding the Ampligen(R) New Drug Application for Chronic Fatigue Syndrome

GlobeNewswire (Aug 14, 2012)
Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2012

GlobeNewswire (Aug 8, 2012)
Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen(R) New Drug Application for Chronic Fatigue Syndrome

GlobeNewswire (Aug 1, 2012)
Hemispherx Biopharma Announces Filing a New Drug Application in Argentina for Ampligen(R) to Treat Chronic Fatigue Syndrome

GlobeNewswire (Jul 18, 2012)
Hemispherx Biopharma and the FDA Reach Agreement on Filing Requirements for the Company's Complete Response in Support of Ampligen(R) New Drug Application for Chronic Fatigue Syndrome Treatment

GlobeNewswire (Jul 11, 2012)

HEB vs. ETF Alternatives

Company Description

We are a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company was founded in the early 1970s... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, April 5, 11:09 AM BioCryst Pharmaceuticals (BCRX +17.4%) pops on news that six deaths in China have been linked to a new strain of avian flu. BCRX is developing peramivir, which has been shown in preclinical studies to help treat highly virulent strains of influenza - including the bird flu strain known as the H5N1 virus. Other drug stocks moving higher on the news: Pure Bioscience (PURE +15.6%), Hemispherx BioPharma (HEB +13.3%), Sinovac Biotech (SVA +7.8%), and Novavax (NVAX +1.1%). Comment! [Healthcare, On the Move]
Monday, March 4, 3:28 PM Hemispherx BioPharma (HEB +0.7%) settles back to trade only marginally higher today, after popping nearly 15% in premarket action after the company's Alferon Injection was approved by Argentina's regulatory agency. Alferon N Injection is an FDA-approved natural interferon and, as Naturaferon, is already approved in Argentina for the treatment of refractory or recurring external genital warts. Comment! [Healthcare, Global & FX, On the Move]
Tuesday, February 5, 10:03 AM Hemispherx (HEB) plummets 13.9% after the FDA again rejects Ampligen, its treatment for chronic fatigue syndrome. As the agency initially said when it first rejected the drug in 2009, it wants Hemispherx to carry out another trial, as the submitted data doesn't provide enough evidence of Ampligen's efficacy or safety. Hemispherx intends to appeal. (previous) (PR) 2 Comments [Healthcare, On the Move]
Friday, December 21, 2012, 4:04 PM Hemispherx Biopharma (HEB -21.2%) gets slammed today after saying the FDA's Arthritis Advisory Committee has shot down its New Drug Application for the marketing of Ampligen for chronic fatigue syndrome by a 9-4 vote, with one abstention. The agency said that, considering the totality of the data, there wasn't sufficient evidence of Ampligen's safety or treatment efficacy. 1 Comment [Healthcare, On the Move]
Thursday, December 20, 2012, 7:21 PM After struggling to make recommendations about the product, an FDA panel rejects Hemispherx Biopharma's (HEB) chronic fatigue syndrome treatment Ampligen, saying it isn't ready for marketing. Several panel members struggled with their decisions because it appears the drug works in certain patients even if it wasn't strongly shown in the clinical data presented to the panel. Shares -20% AH. 7 Comments [Healthcare, On the Move]
Wednesday, December 19, 2012, 10:05 AM Hemispherx Biopharma (HEB) sinks 11.4% after the FDA yesterday placed strong doubts on the the safety and effectiveness of the company's Ampligen treatment for chronic fatigue syndrome. The critique comes ahead of a meeting tomorrow in which an FDA advisory panel will decide whether or not to recommend that the agency authorize the treatment. (previous) 1 Comment [Healthcare, On the Move]
Monday, December 17, 2012, 8:14 AM An FDA advisory panel is due to take another look at Hemispherx Biopharma's (HEB) Ampligen treatment for chronic fatigue syndrome on Thursday after the agency rejected the treatment in 2009. The FDA initially demanded a new trial but accepted Hemispherx's request to reanalyze the study data for Ampligen, which has been in development for a mere two decades. Comment! [Healthcare]
Monday, September 24, 2012, 9:10 AM Premarket gainers: LPH +39%. RMBS +13%. TIVO +10%. STSI +10%. HEB +8%. CPRX +6%.
Losers: PPHM -85%. QCOR -28%. GTAT -8%. FB -6%. AKS -5%. 1 Comment [On the Move]
Tuesday, August 14, 2012, 9:04 AM Hemispherx Biopharma (HEB) jumps 10% after the FDA accepts the company's complete response submission for its New Drug Application for Ampligen, which treats Chronic Fatigue Syndrome. The FDA has set a user-fee data of Feb. 2, 2013, meaning it could make an appoval decision by then. (PR) 1 Comment [On the Move, Healthcare]
Wednesday, January 11, 2012, 10:59 AM Microcap drug developer Hemispherx BioPharma (HEB +16.4%) pops after being granted an extension by the FDA for its pending New Drug Application for Ampligen, a treatment for Chronic Fatigue Syndrome. 1 Comment [Healthcare, On the Move]
Wednesday, November 11, 2009, 9:00 AM Premarket gainers: CHLN +42%. TOL +7%. ING +6%. RFMD +5%. MPEL +5%. HOV +5%. ALU +4%. MBI +4%. HL +4%. GSS +4%. ABK +4%.
Losers: HEB -14%. IRE -5%. M -4%. CVM -4%. Comment!
Tuesday, November 3, 2009, 9:00 AM Premarket gainers: BNI +29%. BDK +24%. KSU +11%. XOMA +7%. CSX +7%. UNP +7%. NSC +7%. SPPI +7%. BZ +6%. CTSH +5%. SWK +5%. BEXP +4%.
Losers: HEB -17%. AIB -16%. RBS -10%. UBS -7%. HEP -6%. WYN -5%. RCL -5%. FOE -5%. CTIC -4%. VALE -4%. AEG -4%. F -4%. HGSI -4%. MGM -4%. STD -4%. MU -4%. Comment!
Monday, October 26, 2009, 9:00 AM Premarket gainers: IO +24%. SUPG +22%. ELGN +19%. ALD +16%. VVUS +13%. BCRX +11%. NVTL +10%. ARNA +8%. MPS +7%. HEB +6%. SVA +5%. MRVL +5%. CVM +5%. RSH +4%. NVAX +4%. CIT +4%.
Losers: PVTB -15%. SOHU -9%. ING -8%. CYOU -8%. TMS -8%. TIVO -4%. Comment!
Thursday, October 15, 2009, 9:00 AM Premarket gainers: ACOR +51%. CIT +11%. PLX +7%. HEB +4%. TSEM +4%.
Losers: MNI -15%. NOK -8%. GNBT -7%. AIB -5%. AIXG -5%. COF -5%. IRE -4%. LVS -4%. GFI -4%. HOG -4%. Comment!
Tuesday, October 13, 2009, 9:00 AM Premarket gainers: PIR +13%. SVA +6%. BZ +5%. HEB +4%. BBI +4%. BQI +4%.
Losers: CIT -18%. ANH -4%. Comment!
Friday, October 9, 2009, 9:00 AM Premarket gainers: SRZ +6%. HEB +6%. HTZ +5%. LAD +5%.
Losers: PZG -8%. Comment!

VFC's Stock House
Stock Watch Wednesday - $DDD, $SSYS, $HP, $ONVO.PK, $PFE, $UTHR, $VNDA, $NVS, $HEB http://bit.ly/cAHZ42
12/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jason F
$HEB Is getting ready for a big move http://stks.co/oFPQ (In-depth Analysis)
11/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://stks.co/hFvF Stocks for Nov 27th: $ACAD, $GNRC, $GOOG, $HEB Market expected to open lower.
11/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

magwitch
HEB announces FDA has confirmed Advisory Cmtee meeting DEC20 re NDA for Ampligen... let the run-up begin :-)
10/22/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joshua Hayes
Big Wave Trading Portfolio Update And Top Current Holdings http://bit.ly/RfRFmV AVD CLGX NTE CAMP SVNT VRNM CSU MAGS RBGPF.PK ASTM HEB
10/21/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

cherrybomb
Ive been watching HEB stock for 3 years! Is it going to happen?
9/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://stks.co/f2AV New Upcoming FDA approval list for 2012 - 2013 $KIPS, $OMER, $AMRN, $HEB, $BMTI, $PATH, $ONXX, $GSK, $POZN, $SLXP
7/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dr. Kris
Power Movers: Short-term big gainers with potential to move sharply in either direction: $BVTI (+7%), $DWCH (+9%), $HEB (+24%), $GSVC (+19%)
1/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

timtrading123
Bullish Engulfing $EJ,$EWW,$FEED.OB,$FRE,$GFIG,$GILD,$HEB,$MAG,$UCBI,$WMB http://bit.ly/rqwvEG
7/28/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

T1aris
HEB Chart BREAKOUT today~Broke thru big resistance at .64 now setup for nice gap and run! HEB
1/6/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

HEB Hemispherx Biopharma, Inc

HEB

Hemispherx Biopharma, Inc